Rafferty Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Rafferty Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-59,464	Closed	-$6.38M	–	1166
2023 Q1	$6.38M	Sell	59,464 -13,725	-19%	-$1.58M	0.04%	325
2022 Q4	$8.05M	Sell	73,189 -21,843	-23%	-$1.42M	0.07%	260
2022 Q3	$5.61M	Buy	+95,032	New	+$4.35M	0.06%	314
2022 Q2	–	Sell	-43,860	Closed	-$1.66M	–	1257
2022 Q1	$1.66M	Buy	+43,860	New	+$1.73M	0.01%	667

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Rafferty Asset Management's RXDX Position: Q2 2023 in Review

Rafferty Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 59,464 shares — an estimated $6.38M sold.

Rafferty Asset Management first reported a position in RXDX in Q1 2022 and held it in 4 quarters. The position peaked at $8.05M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Rafferty Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Rafferty Asset Management sold 59,464 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $6.38M.
Rafferty Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Rafferty Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $8.05M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.